Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV-1 Infection.
Biotechnol J
; 16(1): e2000023, 2021 Jan.
Article
in En
| MEDLINE
| ID: mdl-33103367
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
HIV Infections
/
HIV-1
/
Receptors, CCR5
/
Transcription Activator-Like Effector Nucleases
Limits:
Humans
Language:
En
Journal:
Biotechnol J
Journal subject:
BIOTECNOLOGIA
Year:
2021
Type:
Article
Affiliation country:
Germany